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Abstract
Lower respiratory tract infections (LRTI) are the leading cause of death world-wide, with Streptococcus pneumoniae (Pnc) as
the most prevalent pathogen. Local immune mechanisms appear central to protection against the disease, yet they are
poorly characterized. Infections at other, non-respiratory mucosal sites are associated with a transient circulation of mucosa-
originating lymphocytes from the mucosal site to blood and back to the mucosa. The present study explored whether
pathogen-specific plasmablasts appear in the circulation also in patients with infection of the lower respiratory tract. 16
patients with bacteremic Pnc pneumonia and 14 healthy volunteers were explored for circulating plasmablasts secreting
antibodies against their own pathogenic Pnc strain isolated in blood cultures (patients) or against several pathogenic strains
from pneumonia patients (14 controls) or a mixture of nine different purified pneumococcal polysaccharides (8 controls).
Both patients and volunteers were studied for all plasmablasts. The cells were identified with ELISPOT as Pnc-specific
antibody-secreting cells (ASC) and as all immunoglobulin-secreting cells (ISC). High numbers of circulating Pnc-specific ASC
were found in the acute phase of the disease in all patients with pneumonia (median 97 ASC/106 PBMC), but in none of the
controls. IgG isotype predominated in 9/16 patients. The numbers of ISC were significantly higher in the patients than in the
healthy controls, yet Pnc-specific ASC only accounted for 0.7% of all the patients’ ISC.The present study is the first to show
that antigen-specific plasmablasts appear in the circulation in pneumonia, suggesting that pulmonary lypmhocytes
recirculate in humans. Assessing these cells provides a novel tool for studying immune response to antigens encountered at
the LRT.
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Introduction
The mucosa of the respiratory tract is constantly exposed to a
vast variety of inhaled microbes, some of which may bring on
disease. Lower respiratory tract infections (LRTI) are one of the
leading causes of death world-wide [1], with Streptococcus pneumoniae
(Pnc) as the most prevalent pathogen [2]. Colonization of the
upper respiratory tract by Pnc is considered a significant
preliminary step in the course of pneumonia [3–6]. Therefore,
induction of local immune response preventing colonization
appears beneficial in preventing pneumonia [3,5,6].
Even though the local immune mechanisms are considered
essential in the immune defence in the respiratory tract [6–9], the
mucosal immune mechanisms at the lower respiratory tract (LRT)
are scantily characterized. Bronchus-associated lymphoid tissue
(BALT) consists of discrete lymphoid aggregates in the bronchial
mucosa. Like the gut-associated lymphoid tissue (GALT), BALT
contains T and B cells, dendritic cells, macrophages and high
endothelial venules [8,10]. BALT and intestinal mucosa-associated
Peyer’s patches (PP) show many morphological and functional
similarities; both BALT and PP provide entry for the mucosal
pathogens through special epithelial cells (M cells), for example,
and both are involved in the local production of IgA [8,10], the
main Ig-isotype at most mucosal sites [11–14]. However,
differences have also been noted between BALT and PP: in vitro
lymphocyte/endothelial binding, for example, suggests that BALT
and PPs differ in their lymphocyte-binding selectivity [15], and
IgG appears to be more significant in the LRT than the intestine
[5,16].
Probably due to practical and ethical restrictions in sampling at
LRT in humans, the immune mechanisms at this site are not as
well studied as the local system in the intestine. However, with
other not easily accessible mucosal sites, such as the intestine [17–
20], and the urinary tract [21,22], it has proven possible to assess
mucosal immune response using samples of peripheral blood. This
approach is based on the recirculation of activated lymphocytes:
antigen encounter at a mucosal site is followed by a recirculation
of activated lymphocytes via lymphatics and blood back to
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mucosal sites [17–19,21,23,24], where they are responsible for
local antibody production [25–27]. The mucosa-originating
antigen-specific plasmablasts (pre-plasma cells) can be caught
from the circulation before they home to mucosal sites, and
identified as pathogen-specific plasmablasts [17–20,22]. In addi-
tion to homing to the site where the antigen activation took place,
some of the cells appear to home to some other mucosal sites as
well [28]. In this way the different mucosal sites within the
mucosa-associated lymphoid tissues (MALT) are regarded to
communicate with each other with help of migrating lymphocytes
[7,29]. This circulation of activated cells has been suggested to
happen also at the lower respiratory tract: as early as 1980 it was
shown in animal experiments that lymphocytes from PP and
BALT have an equal propensity to repopulate mucosal tissues with
IgA-plasmablasts [30]. Later, it was established in mice that
adoptively transferred influenza-specific T cell clones can be
relocated in the lung [31]. Until now, there have been no studies
exploring whether antigen-specific plasmablasts appear in the
circulation following antigen encounter at the LRT in humans. By
showing an emergence of antigen-specific plasmablasts in the
circulation during pneumonia, the present study not only provides
evidence of a recirculation of pulmonary lymphocytes, but also
presents a less invasive tool for future research into immune
responses elicited at the LRT.
Results
Microbiological analyses
Throat cultures of the eight volunteers tested for pneumococcal
carriage proved all negative. Data on serotype testing was
available for 10/16 pneumococcal strains isolated in the blood
cultures of the pneumonia patients (strains had been tested in a
reference laboratorium in the National Institute for Health and
Welfare, Helsinki). Five of them had serotype 14, the others
serotype 4, 6B, 7F, 9V and 23F, each in one case.
ASC response in patients with pneumonia
No Pnc-specific ASC were found in the circulation of any of the
healthy volunteers regardless of whether pneumococcal strains of
pneumonia patients (two strains both tested in six volunteers, eight
strains each tested in eight volunteers) or a mixture of nine
capsular polysaccharides (tested in eight volunteers) was used as
antigen. In contrast, all patients with pneumonia exhibited
circulating ASC specific to their own Pnc strain on day 7–10
after the onset of symptoms (Figure 1).
In patients with pneumonia, the median of the total number of
pathogen-specific ASC (IgA+IgG+IgM) was 97/106 PBMC (min-
max 21–6112). There were eight moderate responders (10–100
ASC/106), six high responders (100–1000 ASC/106) and two very
high responders (1,000–10,000 ASC/106) (Figure 2). The medians
of IgA-, IgG- and IgM-ASC are shown in Figure 3. The
predominating isotype was IgA in 5/16, IgG in 9/16 and IgM
in 2/16 patients (Figure 1). In a representative case, a comparison
between ELISPOT assays using the patient’s own Pnc-strain or a
mixture of Pnc polysaccharide antigens revealed a significant
response in both assays. The mixture of polysaccharide antigens
did not prove any inferior to the patient’s own strain (52 against
own Pnc strain vs. 73 ASC/106 PBMC against mixture of capsular
polysaccharides).
All ISC in patients with pneumonia and in healthy
controls
IgG-ISC among patients and volunteers were found to be
normally distributed while IgA-and IgM-ISC and the sum
(IgA+IgG+IgM)-ISC were not. In patients with pneumonia, the
median of the number of all ISC (IgA+IgG+IgM) was 13,181/106
PBMC (min – max 3630–48,773) (Figure 3). This was significantly
higher than the number of ISC in healthy controls (median 1,193/
106 PBMC; min - max 383–3,000, p,0.001 with Mann Whitney
U test). The numbers of all ISC was higher in patients than in
controls even when the numbers of Pnc-specific ASC were
subtracted from the numbers of all patient ISC (median of ‘‘all
patient ISC minus specific ASC’’ was 10,761/106 PBMC; min -
max 3,552–42,661; comparison to all control ISC p,0.001 with
Mann Whitney U test). The numbers of Pnc-specific ASC
represented only 0.7% of ISC in patients with pneumonia.
Discussion
Mucosal exposure to S. pneumoniae induces both mucosal and
systemic humoral and cellular immune responses [6], all
considered to contribute to the protection against pneumonia.
Recurrences of Pnc pneumonia rarely occur in immunocompetent
patients [32–34], which suggests that the disease would induce
host immunity against recurrent infections. Accordingly, it appears
beneficial with Pnc vaccines, too, to induce responses mimicking
natural responses. Because of practical and ethical restrictions on
sampling at LRT in humans, however, the immune mechanisms
in a natural infection are poorly characterized. For studying them,
less invasive means are needed. A practicable option could be the
identification of BALT-originating plasmablasts in the circulation
of patients after antigen encounter at the LRT.
The present study is the first to show that pathogen-specific
plasmablasts appear in the circulation in LRTI in humans. This
finding, novel for LRTI, accords with previous studies, showing a
transient appearance of circulating pathogen-specific plasmablasts
in infections located at other human mucosal sites, for example
bacterial gastroenteritis [18,19,35], urinary tract infection [21,22],
and upper respiratory tract infection [36], and, respectively, after
mucosal vaccinations, such as oral [17,20,23], rectal [28] and
intranasal [37] vaccinations. These cells are considered to
represent lymphocytes that after antigen encounter recirculate
from one mucosal site to the same and some others within the
MALT, which explains why mucosal immunization at one site can
Figure 1. Plasmablast response in pneumococcal pneumonia.
Numbers of pathogen-specific plasmablasts identified as antibody-
secreting cells/106 PBMC in IgA-, IgG- and IgM-isotypes in 16 patients
with acute Streptococcus pneumoniae pneumonia. The IgA, IgG and IgM
values of each individual volunteer are connected with a line.
doi:10.1371/journal.pone.0034334.g001
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lead to immune response at a distant site [8,28]. The current
finding of pathogen-specific plasmablasts in patients with pneu-
monia not only suggests that mucosal cells from the LRT migrate
in humans, but also provides evidence that BALT participates in
the lymphocyte-based communication between the different sites
of the MALT.
Figure 2. Levels of Pnc-specific plasmablasts and all plasmablasts in patients and controls. Percentage of pneumonia patients (n = 16)
with indicated number of pathogen-specific ASC (A) and all ISC (immunoglobulin-secreting cells) (B) and percentage of healthy volunteers with
indicated number of pathogen-specific ASC (C) and all ISC (D). ASC and ISC numbers are both presented as sum of IgA-, IgG- and IgM-secreting cells.
doi:10.1371/journal.pone.0034334.g002
Figure 3. The numbers of ISC in patients with pneumonia and in healthy volunteers. The bars indicate medians of all ISC in IgA-, IgG- and
IgM-isotypes. The statistical analysis was performed with independent samples t-test for IgG-ISC and with Mann Whitney U for the others. Statistical
significances in comparison to numbers of ISC in healthy volunteers are indicated by asterisks (*** p,0.001; * 0.01,p,0.05). The numbers of
volunteers from whom the data were pooled are indicated under each bar.
doi:10.1371/journal.pone.0034334.g003
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So as to ensure that we would measure plasmablasts specific to
the causative microbe of the pneumonia in each patient, we opted
for investigating the response to each patient’s own Pnc isolate,
and only bacteremic patients were enrolled. Thus, even if the first
encounter with the pathogen took place in the respiratory tract,
because of the bacteremia some systemic stimulation was also
likely to appear. The bacteremic period appears very short in
comparison with the infection at the LTR and, therefore, a major
immunological impact of the bacteremic condition is unlikely. This
accords with the results of our previous study where pathogen-
specific ASC were found both in bacteremic and nonbacteremic
patients with a clinical picture and urine findings consistent with
pyelonephritis [21].
Interestingly, in the present study, IgG predominated in 9/16
and IgA in 5/16 cases. The IgG predominance could be
interpreted as a systemic influence on the response. However,
this finding also accords with previous studies indicating that IgG
per se may have a more pronounced defense role than IgA in the
LRT [5,16], and with the fact that mucosal exposure to Pnc
induces both systemic and mucosal immune responses [6]. These
data attest to the possibly integrated induction of respiratory and
systemic immunity suggested in a previous study of recurrent
infections of human upper airways [38].
While the advantages of investigating local immune response in
the LRT simply from blood samples are obvious, two specific
points need to be taken into consideration when applying this
approach. The first is the availability of the pathogens to be used
as antigens. In bacteremia the pathogen can be recovered in blood
culture, but in non-bacteremic patients a preselected antigen panel
should be made available. To compare these alternatives, we
studied one representative patient with both his own Pnc strain
and a mixture of nine capsular polysaccharides of representative
Pnc serotypes as antigens in the assay. The results suggest that
both methods can be applied. The same mixture of common
capsular polysaccharide types may be used for all patients, keeping
in mind the limitation that only the serotypes chosen for the
mixture are covered. The second point to be considered is the
timing of the sampling, as pathogen-specific ASC are only
expected to be found in the circulation transiently, i.e. for less
than one week, before they home to their destination in the tissues.
This timing is based on the kinetics of mucosa-originating
plasmablast response in studies with oral vaccines: ASC have
been shown to appear in the blood on day 3, peak around day 7,
and be undetectable again on day 14 [23]. However, we have
recently detected in a natural infection, in patients with
gastroenteritis, that the pathogen’s persistence at a mucosal site
can be associated with a prolonged recruitment of pathogen-
specific plasmablasts in the blood [35]. It remains to be confirmed
whether the time window could also in studies of LRTI be
extended beyond the days 7–10 used in the present study.
Another point to note in the immune response to Pnc
pneumonia was the exceptionally high total number of all
plasmablasts (ISC) in all our patients’ circulation. The numbers
by far exceeded those of ISC in healthy volunteers even if the
increase caused by Pnc-specific plasmablasts was taken into
account. A similar situation has been reported in other mucosal
infections, such as bacterial gastroenteritis [18] and upper urinary
tract infection [21], but not in lower urinary tract infection [21] or
after oral typhoid vaccination [29]. It thus appears to be a feature
of serious infections, possibly implying polyclonal stimulation
[18,21]. This conception is supported by our observation of
plasmablasts reactive with an irrelevant antigen, trinitrophenyl
in patients with gastroenteritis [18]. A polyclonal stimulation
associated with serious infections could be part of the mechanisms
of life-long immunity, where by-stander-stimulation has been
suggested as a mechanism of keeping memory to unrelated
antigens [39,40].
In conclusion, pathogen-specific plasmablasts (ASC) appear in
the circulation of patients with pneumonia, which provides
evidence on a participatory role of the respiratory tract in the
lymphocyte-based communication between the various sites of the
MALT. The response is accompanied by a significant increase in
the total numbers of plasmablasts (ISC), greater than what the
Pnc-specific plasmablasts account for, thus suggesting a polyclonal
stimulation. Recognizing the time limitations posed by the
transient appearance of antigen-specific plasmablasts, a new tool
for future investigations into immune response in lower respiratory
tract infections is provided.
Materials and Methods
Pathogen-specific ASC and all ISC were explored in samples of
peripheral blood of patients with bacteremic Pnc-pneumonia and
in healthy volunteers.
Patients, healthy volunteers, vaccines and samples
This study protocol was in accordance with the ethical
standards of the responsible regional committee on human
experimentation and with the Helsinki Declaration of 1975 (as
revised in 1983) and was approved by the ethics committees of the
Department of Medicine in Helsinki University Central Hospital
and the Central Hospital of Central Finland. Written informed
consent was obtained from all patients and volunteers.
16 patients (eight women and eight men, aged 30–67 years)
treated in Helsinki University Central Hospital or Central
Hospital of Central Finland for acute pneumonia caused by
Streptococcus pneumoniae and 14 healthy volunteers were enrolled.
One patient in the pneumonia group had asthma, coronary heart
disease and diabetes, one had chronic atrial fibrillation and two
had coronary heart disease as permanent diagnoses. Two were
smokers and one was very obese. The diagnosis of Pnc pneumonia
was based on the following criteria: (1) clinical symptoms of acute
pneumonia: onset of dyspnoea and/or cough within the last 10
days and fever $38uC (2) verified new pulmonary infiltrates by
chest X-ray, (3) enhanced serum levels of C-reactive protein
(.50 mg/ml) and (4) blood culture yielding S. pneumoniae. The
group of healthy volunteers (nine women and five men, aged 18–
50) had no underlying diseases; one of them had a history of
community-acquired pneumonia several years earlier.
All volunteers provided one sample of venous blood and, in
addition, eight controls provided a throat culture to identify a
potential pneumococcal carrier status. In the pneumonia group,
the blood sample was drawn 7–10 days after the onset of
symptoms of respiratory tract infection. This timing was based on
our previous studies on mucosal [17,23] and parenteral [28]
antigen administration indicating that ASC are found in the
circulation only transiently with a peak around 7 days after antigen
encounter. Peripheral blood mononuclear cells (PBMC) were
isolated using Ficoll-Paque and analyzed with enzyme-linked
immunospot assay (ELISPOT) for numbers of Pnc-specific ASC
and for total numbers of immunoglobulin-secreting cells (ISC) of
IgA, IgG and IgM isotypes.
Antigen
For patients with pneumonia, each patient’s own S. pneumoniae-
strain isolated from blood culture was grown on chocolate agar
plates, formalin-killed and used as antigen in the ELISPOT assay
as described previously [18]. To explore a possible use of capsular
Pnc-Specific Plasmablasts in Pneumonia
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polysaccharide as antigens in the assay, one representative patient
with Pnc-pneumonia was analyzed both with a Pnc-specific
ELISPOT assay using the patient’s own Pnc-strain (serotype 14)
and an assay with a mixture of purified capsular polysaccharides
(10 mg/ml of each type 3, 4, 5, 6B, 7F, 8, 14, 19F, 23F; ATCC,
Bethesda, Maryland). For healthy volunteers, the coating antigen
was either this same mixture of nine polysaccharide strains (8
volunteers) or a single Pnc-strain isolated from pneumonia
patients: 6 volunteers were tested for 2 strains (serotypes 9V and
14) and 8 volunteers for 8 strains (serotypes 3, 4, 5, 6B, 7F, 8, 14
and 23F).
ELISPOT assay of specific ASC and ISC
The isolated PBMC were assayed for pathogen-specific ASC
and all ISC using ELISPOT as described previously [23]. In brief,
96-well microtiter plate wells were coated for the antigen-specific
ASC-assay with a whole-cell preparation of formalin-killed S.
pneumoniae strain or with a mixture of nine different purified
pneumococcal capsular polysaccharide types (see above). In the
ISC-assay, the plates were coated with a capturing antibody
against human IgA (rabbit anti-human IgA, Dako, Glostrup,
Denmark), IgG (goat anti-human IgG, Sigma St. Louis, MO) and
IgM (rabbit anti-human IgM; Dako). The wells were washed and
blocked with 1% BSA-PBS. The cells were incubated in the wells
for 2–3 hours, and antibodies secreted during this time were
detected with alkaline phosphatase-conjugated goat anti-human
IgA (Sigma), IgG (Sigma) or IgM. (Shouthern Biotech, Birming-
ham, USA). The substrate (5-bromo-4-chloro-3-indolyl phosphate
p-toluidine salt; Sigma) was added in melted agarose. The spots
were enumerated under a light microscope, and each spot was
interpreted as a print of one antibody-secreting cell. In three
pneumonia patients, the background in the IgG-ISC prohibited
counting the exact values but allowed rough estimation of the level
of IgG-ISC.
Statistics
ASC/ISC were characterized using medians and range of
values. The distribution of the data was tested with Shapiro-Wilk’s
test. If the data were found to be normally distributed, the
statistical analyses were carried out with independent samples t-
test and if not, Mann Whitney U test was used. Differences were
considered significant only when p,0,05. Statistical analyses were
carried out using SAS system for Windows, Version 9.2 (SAS
Institute Inc, Cary, NC, USA).
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